These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 776125)

  • 21. Clinical and histologic correlation of melanoma regression after intralesional BCG therapy: a case report.
    Mastrangelo MJ; Kim YH; Bornstein RS; Chee DO; Sulit HL; Yarbro JW; Prehn RT
    J Natl Cancer Inst; 1974 Jan; 52(1):19-24. PubMed ID: 4590009
    [No Abstract]   [Full Text] [Related]  

  • 22. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Feun LG; Gutterman J; Burgess MA; Hersh EM; Mavligit G; McBride CM; Benjamin RS; Richman SP; Murphy WK; Bodey GP; Brown BW; Mountain CF; Leavens ME; Freireich EJ
    Cancer; 1982 Oct; 50(8):1656-63. PubMed ID: 7116298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
    Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
    Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA; Rapp HJ
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
    McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
    Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of systemic BCG therapy in advanced melanoma.
    El-Domeiri AA; Nika B; Hsia WC; Crispen R; Sabet TY; Gupta TK
    Arch Surg; 1977 Mar; 112(3):257-9. PubMed ID: 843215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
    Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
    Front Immunol; 2018; 9():411. PubMed ID: 29552014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 32. Malignant melanoma.
    Lichtenfeld JL
    Med Clin North Am; 1977 Sep; 61(5):1013-25. PubMed ID: 330971
    [No Abstract]   [Full Text] [Related]  

  • 33. Failure of adjuvant immunotherapy to prevent central nervous system metastases in malignant melanoma patients.
    Grooms GA; Eilber FR; Morton DL
    J Surg Oncol; 1977; 9(2):147-53. PubMed ID: 325299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M; Schenk M; Lee DJ
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R; Wybran J; Epstein W
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
    MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
    Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
    Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
    Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.